Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Iran Biomed J ; 19(1): 51-6, 2015.
Article in English | MEDLINE | ID: mdl-25605490

ABSTRACT

BACKGROUND: Glaucomatous neuropathy is a type of cell death due to apoptosis. The p53 gene is one of the regulatory genes of apoptosis. Recently, the association between the p53 gene encoding for proline at codon 72 and primary open-angle glaucoma (POAG) has been studied in some ethnic groups. This study is the first association analysis of POAG and p53 codon 72 polymorphism in Iranian patients. METHODS: A cohort of 65 unrelated patients with POAG (age range from 12-62 years, mean ± SD of 40.16 ± 17.51 years) and 65 unrelated control subjects (without glaucoma, age range of 14-63 years, mean ± SD of 35.64 ± 13.61 years) were selected. In Iranian POAG patients and normal healthy controls, the p53 codon 72 polymorphism in exon 4 was amplified using polymerase chain reaction. The amplified DNA fragments were digested with the BstUI restriction enzyme, and the digestion patterns were used to identify the alleles for the polymorphic site. RESULTS: Comparisons revealed significant differences in allele and genotype frequencies of Pro72Arg between POAG patients and control group. A higher risk of POAG was associated with allele Pro (OR = 2.1, 95% CI = 1.2-3.4) and genotype Pro/Pro (OR = 3.9, 95% CI = 0.13-12.7). CONCLUSION: The p53 Pro72 allele was more frequent in Iranian POAG patients than in the control group (P<0.05). The present findings show that the individuals with the Pro/Pro genotype may be more likely to develop POAG. However, additional studies are necessary to confirm this association.


Subject(s)
Glaucoma/genetics , Tumor Suppressor Protein p53/genetics , Adolescent , Adult , Apoptosis/genetics , Base Sequence , Child , DNA/genetics , Female , Gene Frequency , Genetic Association Studies , Genotype , Humans , Iran , Male , Middle Aged , Polymorphism, Single Nucleotide , Sequence Analysis, DNA , Young Adult
3.
Asian Pac J Cancer Prev ; 15(4): 1585-8, 2014.
Article in English | MEDLINE | ID: mdl-24641372

ABSTRACT

BACKGROUND: Data regarding childhood and adolescent non Hodgkin lymphomas in Iran are limited. The aim of this study was to assess the epidemiological and histomorphological features and survival of affected patients in our center. MATERIALS AND METHODS: The clinicopathologic features and outcome of 44 children and adolescents with non Hodgkin lymphoma diagnosed during 2004-2012, were investigated retrospectively. The influence of potential prognostic parameters in overall survival was investigated by log-rank test and Cox regression analysis. RESULTS: The mean age at presentation was 13.8 ± 6.16 years with a male predilection (M: F=3:1). Malignant lymphoma, not otherwise specified, diffuse large cell lymphoma and Burkitt lymphoma were the three most common histological types observed. The tumors were 36.4% intermediate grade, 27.3% high grade and 34.1% belonged to the malignant lymphoma not otherwise specified group. Immunohistochemistry findings were available in 39 cases. Out of these cases 33 (84.6%) had B cell lineage, 4 (10.25%) T cell lineage and 2 (5.12%) of the cases belonged to miscellaneous group. 3 year and 5 year survivals were 48% and 30% respectively and median survival was 36 months (95%CI=21.7-50.3 months). Overall survival in patients with high grade tumors was 19.5 months, in the intermediate group,79 months , and for malignant lymphomas not otherwise specified it was 33.6 months (p value=0.000). CONCLUSIONS: The survival rate for children and adolescents with non Hodgkin lymphomas at our center during 2004-2012 was at a low level.


Subject(s)
Lymphoma, Non-Hodgkin/epidemiology , Lymphoma, Non-Hodgkin/mortality , Adolescent , Biomarkers, Tumor , Burkitt Lymphoma/drug therapy , Burkitt Lymphoma/epidemiology , Burkitt Lymphoma/mortality , Cell Lineage/immunology , Female , Humans , Immunohistochemistry , Iran/epidemiology , Lymphoma, B-Cell/drug therapy , Lymphoma, B-Cell/epidemiology , Lymphoma, B-Cell/mortality , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/epidemiology , Lymphoma, Large B-Cell, Diffuse/mortality , Lymphoma, Non-Hodgkin/drug therapy , Male , Retrospective Studies , Survival Rate , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...